Ketone Bodies Induce Unique Inhibition of Tumor Cell Proliferation and Enhance the Efficacy of Anti-Cancer Agents.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory cell culture study with no human or animal data.
PubMed 37760956 · doi:10.3390/biomedicines11092515
What was done
Researchers tested the effects of ketone bodies—specifically sodium acetoacetate (NaAcAc), lithium acetoacetate (LiAcAc), sodium 3-hydroxybutyrate (3-HB), and lithium chloride (LiCl)—on the proliferation of multiple human cancer cell lines, including ovarian, cervical, breast, and colon (SW480) cancers. They also evaluated cell-killing efficacy when combining ketone bodies with anticancer agents: rapamycin, methotrexate, and the anticancer peptide PNC-27.
What was found
NaAcAc cytostatically inhibited cancer cell proliferation rather than directly killing cells across the tested cell lines. LiCl alone also exerted growth-inhibitory effects, with LiAcAc exhibiting combined effects of both acetoacetate and lithium ions. When co-administered with rapamycin, methotrexate, or PNC-27, ketone bodies substantially lowered the IC50 values required for cancer cell killing. The abstract reported no exact numerical values, concentrations, or statistical parameters.
Why it matters
The findings demonstrate in vitro that ketone bodies can slow cancer cell replication and sensitize tumor cells to chemotherapeutic and peptide agents, supporting further mechanistic exploration of ketogenic adjunctive therapies.
Limits
This is exclusively an in vitro cell culture experiment lacking animal model validation or human clinical data. The abstract provides no specific concentrations, IC50 measurements, cell viability percentages, or effect sizes, precluding assessment of whether therapeutic concentrations are physiologically achievable in humans without toxicity.
Cited by
- partial The addition of ketones to cancer cells decreases their proliferation via a ketone-induced reduction in the glycolytic enzyme hexokinase.